JNJCongressional Stock Trades
Johnson & Johnson
Pharmaceutical Preparations
Congressional stock trades in Johnson & Johnson (JNJ) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
54
Politicians Trading
21
Last Traded
Sep 8, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Josh GottheimerD | Feb 10, 2025 | Jan 16, 2025 | Buy | $1,001 - $15,000 | +83.10% |
| Marjorie Taylor GreeneR | Jan 27, 2025 | Jan 8, 2025 | Buy | $1,001 - $15,000 | +90.17% |
| Marjorie Taylor GreeneR | Jan 27, 2025 | Jan 8, 2025 | Buy | $1,001 - $15,000 | +90.17% |
| Marjorie Taylor GreeneR | Jan 27, 2025 | Jan 8, 2025 | Buy | $1,001 - $15,000 | +90.17% |
Page 2 of 2
Price History
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
21 members of Congress have disclosed 54 trades in Johnson & Johnson (JNJ). Most active: Lisa C. McClain (6), Thomas H. Kean, Jr. (6), Josh Gottheimer (5).
Across all disclosures, members of Congress reported 23 purchases and 31 sales of Johnson & Johnson (JNJ). The most recent trade was on Sep 8, 2026.
Lloyd Doggett disclosed buying Johnson & Johnson (JNJ) on Sep 8, 2026, valued at $1,001 - $15,000.
Thomas H. Kean, Jr. disclosed selling Johnson & Johnson (JNJ) on Aug 27, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.